{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:22:17Z","timestamp":1776133337735,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-04736-2","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T14:52:42Z","timestamp":1745333562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Optimal duration of anticoagulation after left atrial appendage closure: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Xuan","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaona","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"issue":"1","key":"4736_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","volume":"64","author":"DR Holmes Jr","year":"2014","unstructured":"Holmes DR Jr, et al. \u201cProspective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial,\u201d (in eng). J Am Coll Cardiol. 2014;64(1):1\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"4736_CR2","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1001\/jama.2014.15192","volume":"312","author":"VY Reddy","year":"2014","unstructured":"Reddy VY, et al. \u201cPercutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial,\u201d (in eng). JAMA. 2014;312(19):1988\u201398.","journal-title":"JAMA"},{"issue":"24","key":"4736_CR3","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","volume":"70","author":"VY Reddy","year":"2017","unstructured":"Reddy VY, et al. \u201c5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials,\u201d (in eng). J Am Coll Cardiol. 2017;70(24):2964\u201375.","journal-title":"J Am Coll Cardiol"},{"issue":"9689","key":"4736_CR4","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","volume":"374","author":"DR Holmes","year":"2009","unstructured":"Holmes DR, et al. \u201cPercutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial,\u201d (in eng). Lancet. 2009;374(9689):534\u201342.","journal-title":"Lancet"},{"issue":"1","key":"4736_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, et al. \u201c2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines,\u201d (in eng). Circulation. 2024;149(1):e1\u2013156.","journal-title":"Circulation"},{"issue":"18","key":"4736_CR6","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2022.02.047","volume":"79","author":"JV Freeman","year":"2022","unstructured":"Freeman JV, et al. \u201cAntithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation,\u201d (in eng). J Am Coll Cardiol. 2022;79(18):1785\u201398.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"4736_CR7","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.jacc.2023.08.010","volume":"82","author":"PEP Carvalho","year":"2023","unstructured":"Carvalho PEP, et al. \u201cNetwork Meta-Analysis of Initial Antithrombotic Regimens After Left Atrial Appendage Occlusion,\u201d (in eng). J Am Coll Cardiol. 2023;82(18):1765\u201373.","journal-title":"J Am Coll Cardiol"},{"key":"4736_CR8","doi-asserted-by":"crossref","unstructured":"R. R. Tilz et al., \"Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association Survey,\" (in eng), Europace. 2017;19(10),1737\u20131742.","DOI":"10.1093\/europace\/eux254"},{"issue":"11","key":"4736_CR9","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.jcin.2023.01.011","volume":"16","author":"J Saw","year":"2023","unstructured":"Saw J, et al. \u201cSCAI\/HRS Expert Consensus Statement on Transcatheter Left Atrial Appendage Closure,\u201d (in eng). JACC Cardiovasc Interv. 2023;16(11):1384\u2013400.","journal-title":"JACC Cardiovasc Interv"},{"issue":"7","key":"4736_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.jcin.2014.03.003","volume":"7","author":"S Kar","year":"2014","unstructured":"Kar S, et al. \u201cImpact of Watchman and Amplatzer devices on left atrial appendage adjacent structures and healing response in a canine model,\u201d (in eng). JACC Cardiovasc Interv. 2014;7(7):801\u20139.","journal-title":"JACC Cardiovasc Interv"},{"issue":"12","key":"4736_CR11","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1111\/j.1540-8167.2012.02360.x","volume":"23","author":"L Massarenti","year":"2012","unstructured":"Massarenti L, Yilmaz A. \u201cIncomplete endothelialization of left atrial appendage occlusion device 10 months after implantation,\u201d (in eng). J Cardiovasc Electrophysiol. 2012;23(12):1384\u20135.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"4736_CR12","doi-asserted-by":"crossref","unstructured":"S. P. Sharma, D. Singh, D. Nakamura, R. Gopinathannair, and D. Lakkireddy, \"Incomplete endothelialization of WatchmanTM Device: Predictors and Implications from Two Cases,\" (in eng), J Atr Fibrillation. 2019;11(5)2162.","DOI":"10.4022\/jafib.2039"},{"issue":"2","key":"4736_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10554-022-02721-w","volume":"39","author":"J Xu","year":"2023","unstructured":"Xu J, et al. \u201cClinical relevance of incomplete device endothelialization after left atrial appendage closure,\u201d (in eng). Int J Cardiovasc Imaging. 2023;39(2):451\u20139.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"10","key":"4736_CR14","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.121.057859","volume":"145","author":"R Galea","year":"2022","unstructured":"Galea R, et al. \u201cAmulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial,\u201d (in eng). Circulation. 2022;145(10):724\u201338.","journal-title":"Circulation"},{"key":"4736_CR15","doi-asserted-by":"crossref","unstructured":"X. Freixa et al. \u201cLow-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: The ADALA Randomized Clinical Trial.\u201d JAMA cardiology. 2024;9(10):922\u2013926.","DOI":"10.1001\/jamacardio.2024.2335"},{"issue":"7","key":"4736_CR16","doi-asserted-by":"publisher","first-page":"e008481","DOI":"10.1161\/CIRCINTERVENTIONS.119.008481","volume":"13","author":"G Duthoit","year":"2020","unstructured":"Duthoit G, et al. \u201cReduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study,\u201d (in eng). Circ Cardiovasc Interv. 2020;13(7):e008481.","journal-title":"Circ Cardiovasc Interv"},{"issue":"1","key":"4736_CR17","first-page":"4","volume":"19","author":"A Tzikas","year":"2017","unstructured":"Tzikas A, et al. \u201cPercutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies,\u201d (in eng). Europace. 2017;19(1):4\u201315.","journal-title":"Europace"},{"issue":"11","key":"4736_CR18","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. \u201cDefinition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH,\u201d (in eng). J Thromb Haemost. 2015;13(11):2119\u201326.","journal-title":"J Thromb Haemost"},{"issue":"23","key":"4736_CR19","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, et al. \u201cStandardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium,\u201d (in eng). Circulation. 2011;123(23):2736\u201347.","journal-title":"Circulation"},{"issue":"1","key":"4736_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.21037\/apm-21-3654","volume":"11","author":"W Li","year":"2022","unstructured":"Li W, et al. \u201cSafety and efficacy of different anticoagulation regimens after left atrial appendage occlusion,\u201d (in eng). Ann Palliat Med. 2022;11(1):201\u20139.","journal-title":"Ann Palliat Med"},{"issue":"7","key":"4736_CR21","doi-asserted-by":"publisher","first-page":"877","DOI":"10.4244\/EIJ-D-17-00042","volume":"13","author":"MW Bergmann","year":"2017","unstructured":"Bergmann MW, et al. \u201cSafety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry,\u201d (in eng). EuroIntervention. 2017;13(7):877\u201384.","journal-title":"EuroIntervention"},{"key":"4736_CR22","doi-asserted-by":"publisher","first-page":"614762","DOI":"10.3389\/fphar.2021.614762","volume":"12","author":"X Li","year":"2021","unstructured":"Li X, et al. \u201cClinical Efficacy and Safety Comparison of Rivaroxaban and Dabigatran for Nonvalvular Atrial Fibrillation Patients Undergoing Percutaneous Left Atrial Appendage Closure Operation,\u201d (in eng). Front Pharmacol. 2021;12:614762.","journal-title":"Front Pharmacol"},{"key":"4736_CR23","doi-asserted-by":"crossref","unstructured":"J. Y. Ke et al., \"Combined atrial fibrillation ablation and left atrial appendage closure: Watchman vs. LAmbre devices,\" (in eng), Front Cardiovasc Med. 2022;9:1011037.","DOI":"10.3389\/fcvm.2022.1011037"},{"key":"4736_CR24","doi-asserted-by":"crossref","unstructured":"X. Li, Q. Jin, Y. Yao, X. Zhang, and Q. Lv, \"Clinical Effectiveness and Safety Comparison between Reduced Rivaroxaban Dose and Dual Antiplatelet Therapy for Nonvalvular Atrial Fibrillation Patients Following Percutaneous Left Atrial Appendage Closure: A Prospective Observational Study,\". 2023;24(11).","DOI":"10.31083\/j.rcm2411335"},{"key":"4736_CR25","doi-asserted-by":"crossref","unstructured":"M. J. Price et al., \"A Pilot Study of Monotherapy with a Non-Vitamin K-Antagonist Oral Anticoagulant following Watchman Left Atrial Appendage Closure in Patients with Non-Valvular Atrial Fibrillation,\" Structural Heart.\u00a02020;4(4)288\u2013292.","DOI":"10.1080\/24748706.2020.1766162"},{"issue":"1","key":"4736_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10840-021-00958-4","volume":"64","author":"M Ajmal","year":"2022","unstructured":"Ajmal M, Hutchinson MD, Lee K, Indik JH. \u201cOutcomes in patients implanted with a Watchman device in relation to choice of anticoagulation and indication for implant,\u201d (in eng). J Interv Card Electrophysiol. 2022;64(1):1\u20138.","journal-title":"J Interv Card Electrophysiol"},{"key":"4736_CR27","doi-asserted-by":"crossref","unstructured":"X. D. Zhou et al. \u201cReduced- or Half-Dose Rivaroxaban Following Left Atrial Appendage Closure: A Feasible Antithrombotic Therapy in Patients at High Risk of Bleeding?.\u201d Journal of clinical medicine. 2023;12(3):847.","DOI":"10.3390\/jcm12030847"},{"key":"4736_CR28","doi-asserted-by":"crossref","unstructured":"H. Ge et al., \"Risk of device-related thrombosis following short-term oral anticoagulation with low-dose dabigatran versus warfarin after Watchman left atrial appendage occlusion,\" (in eng), Sci Prog.\u00a02022;105(3)368504221113194.","DOI":"10.1177\/00368504221113194"},{"issue":"8","key":"4736_CR29","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.jfma.2021.10.015","volume":"121","author":"G Fu","year":"2022","unstructured":"Fu G, et al. \u201cSafety and efficacy of low-dose non-vitamin K antagonist oral anticoagulants versus warfarin after left atrial appendage closure with the Watchman device,\u201d (in eng). J Formos Med Assoc. 2022;121(8):1488\u201394.","journal-title":"J Formos Med Assoc"},{"key":"4736_CR30","doi-asserted-by":"crossref","unstructured":"Y. Chen, Y. Zhang, L. Qu, W. Huang, X. Su, and Y. Chen, \"Short-term non-vitamin K antagonist oral anticoagulants vs. warfarin in preventing device-related thrombosis after left atrial appendage closure,\" (in eng), J Thromb Thrombolysis.\u00a02021;52(3,)872\u2013879.","DOI":"10.1007\/s11239-021-02408-4"},{"key":"4736_CR31","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2147\/DDDT.S293812","volume":"15","author":"J Zhu","year":"2021","unstructured":"Zhu J, Xu J. \u201cThe Use of Novel Non-Vitamin K Antagonist Oral Anticoagulants Following Closure of the Left Atrial Appendage: Preliminary Results of Clinical Follow-Up,\u201d (in eng). Drug Des Devel Ther. 2021;15:1067\u201373.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"4736_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.hrthm.2016.10.020","volume":"14","author":"Y Enomoto","year":"2017","unstructured":"Enomoto Y, et al. \u201cUse of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device,\u201d (in eng). Heart Rhythm. 2017;14(1):19\u201324.","journal-title":"Heart Rhythm"},{"issue":"3","key":"4736_CR33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/24748706.2021.1890286","volume":"5","author":"B Tjoe","year":"2021","unstructured":"Tjoe B, et al. Use of Direct Oral Anticoagulation Therapy Following Implantation of the Watchman Left Atrial Appendage Occlusion Device. Structural Heart. 2021;5(3):295\u2013301.","journal-title":"Structural Heart"},{"issue":"5","key":"4736_CR34","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jacep.2019.11.009","volume":"6","author":"M Osman","year":"2020","unstructured":"Osman M, et al. \u201cShort-Term Antiplatelet Versus Anticoagulant Therapy After Left Atrial Appendage Occlusion: A Systematic Review and Meta-Analysis,\u201d (in eng). JACC Clin Electrophysiol. 2020;6(5):494\u2013506.","journal-title":"JACC Clin Electrophysiol"},{"issue":"11","key":"4736_CR35","doi-asserted-by":"publisher","first-page":"300060520966478","DOI":"10.1177\/0300060520966478","volume":"48","author":"SY Li","year":"2020","unstructured":"Li SY, Wang J, Hui X, Zhu HJ, Wang BY, Xu H. \u201cMeta-analysis of postoperative antithrombotic therapy after left atrial appendage occlusion,\u201d (in eng). J Int Med Res. 2020;48(11):300060520966478.","journal-title":"J Int Med Res"},{"key":"4736_CR36","doi-asserted-by":"crossref","unstructured":"Mesnier J, et al. \u201cEarly Discontinuation of Antithrombotic Treatment Following Left Atrial Appendage Closure.\u201d The American journal of cardiology. 2022;171:91\u201398.","DOI":"10.1016\/j.amjcard.2022.01.055"},{"issue":"9","key":"4736_CR37","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1161\/CIRCULATIONAHA.118.035090","volume":"138","author":"SR Dukkipati","year":"2018","unstructured":"Dukkipati SR, et al. \u201cDevice-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes,\u201d (in eng). Circulation. 2018;138(9):874\u201385.","journal-title":"Circulation"},{"key":"4736_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.thromres.2022.05.009","volume":"215","author":"EW Aarnink","year":"2022","unstructured":"Aarnink EW, et al. \u201cHemostatic biomarkers and antithrombotic strategy in percutaneous left atrial interventions: State-of-the-art review,\u201d (in eng). Thromb Res. 2022;215:41\u201351.","journal-title":"Thromb Res"},{"key":"4736_CR39","doi-asserted-by":"crossref","unstructured":"Rod\u00e9s-Cabau J, et al. \u201cChanges in Coagulation and Platelet Activation Markers Following Transcatheter Left Atrial Appendage Closure.\u201d The American journal of cardiology. 2017;120(1):87\u201391.","DOI":"10.1016\/j.amjcard.2017.03.253"},{"issue":"7","key":"4736_CR40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.008481","volume":"13","author":"G Duthoit","year":"2020","unstructured":"Duthoit G, et al. \u201cReduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study,\u201d Circulation. Cardiovascular interventions, Journal article. 2020;13(7): e008481.","journal-title":"Cardiovascular interventions, Journal article"},{"issue":"38","key":"4736_CR41","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, et al. \u201c2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS,\u201d (in eng). Eur Heart J. 2016;37(38):2893\u2013962.","journal-title":"Eur Heart J"},{"issue":"7","key":"4736_CR42","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1161\/STROKEAHA.113.000990","volume":"44","author":"M Hori","year":"2013","unstructured":"Hori M, et al. \u201cDabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation,\u201d (in eng). Stroke. 2013;44(7):1891\u20136.","journal-title":"Stroke"},{"key":"4736_CR43","doi-asserted-by":"crossref","unstructured":"Goto S, et al. \u201cEfficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial,\u201d (in eng). Am Heart J. 2014;168(3):303\u20139.","DOI":"10.1016\/j.ahj.2014.06.005"},{"issue":"6","key":"4736_CR44","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1161\/STROKEAHA.113.002968","volume":"45","author":"KS Wong","year":"2014","unstructured":"Wong KS, et al. \u201cRivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial,\u201d (in eng). Stroke. 2014;45(6):1739\u201347.","journal-title":"Stroke"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04736-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04736-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04736-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T14:52:59Z","timestamp":1745333579000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04736-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4736"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04736-2","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical and IRB approval of this analysis were not required as no human or animal subjects were involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"304"}}